Your browser doesn't support javascript.
loading
Switching from intravenous to subcutaneous formulation of abatacept: a single-center Italian experience on efficacy and safety.
Reggia, Rossella; Franceschini, Franco; Tincani, Angela; Cavazzana, Ilaria.
Afiliação
  • Reggia R; From the Rheumatology and Clinical Immunology Department, Spedali Civili and University of Brescia, Brescia, Italy.R. Reggia, MD; F. Franceschini, MD; A. Tincani, MD; I. Cavazzana, MD, Rheumatology and Clinical Immunology Department, Spedali Civili and University of Brescia. rossella.reggia@gmail.co
  • Franceschini F; From the Rheumatology and Clinical Immunology Department, Spedali Civili and University of Brescia, Brescia, Italy.R. Reggia, MD; F. Franceschini, MD; A. Tincani, MD; I. Cavazzana, MD, Rheumatology and Clinical Immunology Department, Spedali Civili and University of Brescia.
  • Tincani A; From the Rheumatology and Clinical Immunology Department, Spedali Civili and University of Brescia, Brescia, Italy.R. Reggia, MD; F. Franceschini, MD; A. Tincani, MD; I. Cavazzana, MD, Rheumatology and Clinical Immunology Department, Spedali Civili and University of Brescia.
  • Cavazzana I; From the Rheumatology and Clinical Immunology Department, Spedali Civili and University of Brescia, Brescia, Italy.R. Reggia, MD; F. Franceschini, MD; A. Tincani, MD; I. Cavazzana, MD, Rheumatology and Clinical Immunology Department, Spedali Civili and University of Brescia.
J Rheumatol ; 42(2): 193-5, 2015 Feb.
Article em En | MEDLINE | ID: mdl-25512476
ABSTRACT

OBJECTIVE:

Subcutaneous (SC) abatacept (ABA) is comparable to intravenous (IV) formulation in terms of efficacy and safety profile. Our work analyzed the switch to SC formulation from IV administration in patients with rheumatoid arthritis.

METHODS:

Fifty-one patients treated with SC ABA were included. Clinical data were obtained from clinical charts.

RESULTS:

Fourteen patients relapsed and needed to return to the IV administration. Neither clinical and laboratory features nor the previous therapies were identified as risk factors for SC formulation inefficacy. Disease activity decreased after the return to IV infusions.

CONCLUSION:

SC ABA showed a risk of relapse in 27% of cases. The reinsertion of the IV administration quickly reinstated disease control.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Imunoconjugados / Antirreumáticos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: J Rheumatol Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Imunoconjugados / Antirreumáticos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: J Rheumatol Ano de publicação: 2015 Tipo de documento: Article